Companies: 49,246 Total Market Cap: 132441797263938.02

Alkermes plc

NASDAQ: ALKS
Healthcare Drug Manufacturers - Specialty & Generic
Rank #3129
Market Cap 5.17 B
Volume 169,522
Price 31.34
Change (%) 0.35%
Country or region Ireland Ireland

Alkermes plc's latest marketcap:

5.17 B

As of 05/20/2025, Alkermes plc's market capitalization has reached $5.17 B. According to our data, Alkermes plc is the 3129th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 5.17 B
Revenue (ttm) 1.51 B
Net Income (ttm) 352.71 M
Shares Out 164.90 M
EPS (ttm) 2.09
Forward PE 17.36
Ex-Dividend Date n/a
Earnings Date 05/01/2025
Market Cap Chart
Data Updated: 05/20/2025

Alkermes plc's yearly market capitalization.

Alkermes plc has seen its market value grow from $469.60 M to $5.17 B since 1998, representing a total increase of 1,000.51% and an annual compound growth rate (CAGR) of 9.52%.
Date Market Cap Change (%)
05/20/2025 $5.17 B 6.77%
12/31/2024 $4.65 B 0.52%
12/29/2023 $4.63 B 7.82%
12/30/2022 $4.29 B 14.15%
12/31/2021 $3.76 B 18.47%
12/31/2020 $3.18 B -1.2%
12/31/2019 $3.21 B -29.92%
12/31/2018 $4.59 B -45.52%
12/29/2017 $8.42 B -0.36%
12/30/2016 $8.45 B -29.09%
12/31/2015 $11.91 B 39.1%
12/31/2014 $8.56 B 53.99%
12/31/2013 $5.56 B 127.59%
12/31/2012 $2.44 B 8.61%
12/30/2011 $2.25 B 91.59%
12/31/2010 $1.17 B 31.68%
12/31/2009 $891.70 M -12.16%
12/31/2008 $1.02 B -36.29%
12/31/2007 $1.59 B 18.17%
12/29/2006 $1.35 B -22.92%
12/30/2005 $1.75 B 37.76%
12/31/2004 $1.27 B 5.23%
12/31/2003 $1.21 B 197.29%
12/31/2002 $405.90 M -76.06%
12/31/2001 $1.70 B -2.38%
12/29/2000 $1.74 B 39.28%
12/31/1999 $1.25 B 165.57%
12/31/1998 $469.60 M

Company Profile

About Alkermes plc

Alkermes plc is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative pharmaceutical products. The company focuses on addressing unmet medical needs in therapeutic areas across the United States, Ireland, and internationally.

Key Therapeutic Areas

  • Alcohol dependence
  • Opioid dependence
  • Schizophrenia
  • Bipolar I disorder
  • Neurological disorders

Market-Leading Products

Alkermes offers a robust portfolio of proprietary commercial products, including:

  • ARISTADA – An intramuscular injectable suspension for schizophrenia treatment.
  • ARISTADA INITIO – Designed for adults with schizophrenia.
  • VIVITROL – Used for alcohol dependence treatment and opioid dependence prevention.
  • LYBALVI – An oral atypical antipsychotic for schizophrenia and bipolar I disorder.

Technology & Collaborations

The company provides proprietary technology platforms to third parties, enabling them to develop, commercialize, and manufacture advanced pharmaceutical products. Alkermes has strategic collaborations with industry leaders, including:

  • Janssen Pharmaceutica N.V.
  • Janssen Pharmaceutica Inc
  • Janssen Pharmaceutica International

Founded: 1987 | Headquarters: Dublin, Ireland

Frequently Asked Questions

As of 05/20/2025, Alkermes plc (including the parent company, if applicable) has an estimated market capitalization of $5.17 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Alkermes plc global market capitalization ranking is approximately 3129 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Ireland
Founded 1987
IPO Date 07/16/1991
Employees 1,800
CEO Richard Pops
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Address Connaught House, 1 Burlington Road
Dublin, D04 C5Y6
Ireland
Website https://www.alkermes.com
People Also Watch
Zoetis
163.87 0.35%
Merck KGaA
131.89 0.35%
Haleon plc
546.86 0.35%
NSE-SUNPHARMA
19.96 0.35%